Symbols / AVIR Stock $4.42 +4.25% Atea Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
AVIR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jean-Pierre Sommadossi Ph.D.
Exch · Country NMS · United States
Market Cap 353.72M
Enterprise Value 98.35M
Income -169.52M
Sales —
FCF (ttm) -87.71M
Book/sh 2.92
Cash/sh 3.20
Employees 55
Insider 10d —
IPO Oct 30, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.19
PEG —
P/S —
P/B 1.51
P/C —
EV/EBITDA -0.52
EV/Sales —
Quick Ratio 7.67
Current Ratio 7.89
Debt/Eq 0.27
LT Debt/Eq —
EPS (ttm) -2.11
EPS next Y -1.39
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-03-05
ROA -33.52%
ROE -52.58%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 80.03M
Shs Float 60.24M
Insider Own 13.40%
Instit Own 80.14%
Short Float 12.07%
Short Ratio 24.40
Short Interest 7.49M
52W High 6.45
vs 52W High -31.47%
52W Low 2.78
vs 52W Low 58.99%
Beta 0.38
Impl. Vol. 48.37%
Rel Volume 0.78
Avg Volume 444.72K
Volume 345.39K
Target (mean) $8.67
Tgt Median $10.00
Tgt Low $6.00
Tgt High $10.00
# Analysts 3
Recom Buy
Prev Close $4.24
Price $4.42
Change 4.25%
About

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.67
Mean price target
2. Current target
$4.42
Latest analyst target
3. DCF / Fair value
$-19.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.42
Low
$6.00
High
$10.00
Mean
$8.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-09 main Evercore ISI Group Outperform → Outperform $10
2025-04-11 main Morgan Stanley Equal-Weight → Equal-Weight $6
2024-08-13 up Morgan Stanley Underweight → Equal-Weight $7
2023-08-10 down JP Morgan Neutral → Underweight —
2023-03-16 main JP Morgan — → Neutral $8
2023-01-27 main SVB Leerink — → Market Perform $6
2023-01-24 main Morgan Stanley — → Underweight $4
2022-08-15 main Morgan Stanley — → Underweight $7
2022-03-02 main JP Morgan — → Neutral $8
2022-03-01 main SVB Leerink — → Market Perform $9
2022-02-16 main SVB Leerink — → Market Perform $10
2022-01-06 down Morgan Stanley Equal-Weight → Underweight $7
2021-11-18 down SVB Leerink Outperform → Market Perform $11
2021-10-20 main SVB Leerink — → Outperform $20
2021-10-20 down JP Morgan Overweight → Neutral $16
2021-10-05 down Morgan Stanley Overweight → Equal-Weight $55
2021-09-09 init SVB Leerink — → Outperform $60
2021-08-18 main Morgan Stanley — → Overweight $37
2021-06-03 main Morgan Stanley — → Overweight $35
2021-04-06 main Morgan Stanley — → Overweight $82
News
RSS: Latest AVIR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-18 MURPHY POLLY A Director — 6,100 $4.17 $25,446
2026-03-11 CORCORAN ANDREA J Chief Financial Officer — 60,000 $1.24 $74,400
2026-02-03 SOMMADOSSI JEAN-PIERRE Chief Executive Officer — 572,983 $1.24 $372,000
2026-01-30 CORCORAN ANDREA J Officer — 54,866 — —
2026-01-30 FOSTER WAYNE CPA Officer — 41,333 — —
2026-01-30 HORGA MARIA ARANTXA Officer — 51,283 — —
2026-01-30 HAMMOND JANET MJ Officer — 58,050 — —
2026-01-30 VAVRICKA JOHN Officer — 42,083 — —
2025-06-20 DUNCAN BARBARA GAYLE Director — 29,600 — —
2025-06-20 BERGER FRANKLIN MILAN Director — 29,600 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
180.89
-6.25%
192.95
+17.54%
164.16
+25.65%
130.65
Research And Development
148.02
+2.72%
144.10
+26.14%
114.24
+39.43%
81.94
Selling General And Administration
32.86
-32.73%
48.85
-2.14%
49.92
+2.47%
48.71
General And Administrative Expense
32.86
-32.73%
48.85
-2.14%
49.92
+2.47%
48.71
Other Gand A
32.86
-32.73%
48.85
-2.14%
49.92
+2.47%
48.71
Total Expenses
180.89
-6.25%
192.95
+17.54%
164.16
+25.65%
130.65
Operating Income
-180.89
+6.25%
-192.95
-17.54%
-164.16
-25.65%
-130.65
Total Operating Income As Reported
-180.89
+6.25%
-192.95
-17.54%
-164.16
-25.65%
-130.65
EBITDA
-180.47
+6.27%
-192.53
-17.58%
-163.75
-25.58%
-130.39
Normalized EBITDA
-180.47
+6.27%
-192.53
-17.58%
-163.75
-25.58%
-130.39
Reconciled Depreciation
0.42
+0.00%
0.42
+0.00%
0.42
+60.00%
0.26
EBIT
-180.89
+6.25%
-192.95
-17.54%
-164.16
-25.65%
-130.65
Net Income
-158.35
+5.96%
-168.38
-23.85%
-135.96
-17.30%
-115.91
Pretax Income
-164.51
+1.76%
-167.46
-24.10%
-134.94
-12.92%
-119.50
Net Non Operating Interest Income Expense
16.38
-35.76%
25.49
-12.78%
29.22
+162.08%
11.15
Net Interest Income
16.38
-35.76%
25.49
-12.78%
29.22
+162.08%
11.15
Interest Income Non Operating
16.38
-35.76%
25.49
-12.78%
29.22
+162.08%
11.15
Interest Income
16.38
-35.76%
25.49
-12.78%
29.22
+162.08%
11.15
Tax Provision
-6.16
-766.16%
0.93
-9.14%
1.02
+128.36%
-3.59
Tax Rate For Calcs
0.00
-82.19%
0.00
+0.00%
0.00
+577.42%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-158.35
+5.96%
-168.38
-23.85%
-135.96
-17.30%
-115.91
Net Income From Continuing Operation Net Minority Interest
-158.35
+5.96%
-168.38
-23.85%
-135.96
-17.30%
-115.91
Net Income From Continuing And Discontinued Operation
-158.35
+5.96%
-168.38
-23.85%
-135.96
-17.30%
-115.91
Net Income Continuous Operations
-158.35
+5.96%
-168.38
-23.85%
-135.96
-17.30%
-115.91
Normalized Income
-158.35
+5.96%
-168.38
-23.85%
-135.96
-17.30%
-115.91
Net Income Common Stockholders
-158.35
+5.96%
-168.38
-23.85%
-135.96
-17.30%
-115.91
Diluted EPS
—
-2.00
-22.70%
-1.63
-17.27%
-1.39
Basic EPS
—
-2.00
-22.70%
-1.63
-17.27%
-1.39
Basic Average Shares
—
84.26
+1.05%
83.39
+0.17%
83.25
Diluted Average Shares
—
84.26
+1.05%
83.39
+0.17%
83.25
Diluted NI Availto Com Stockholders
-158.35
+5.96%
-168.38
-23.85%
-135.96
-17.30%
-115.91
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
315.22
-32.16%
464.67
-21.90%
594.97
-10.76%
666.71
Current Assets
310.99
-32.74%
462.36
-21.70%
590.46
-10.66%
660.92
Cash Cash Equivalents And Short Term Investments
301.83
-33.62%
454.72
-21.34%
578.11
-10.61%
646.71
Cash And Cash Equivalents
95.71
+47.94%
64.70
-55.02%
143.82
-23.69%
188.46
Other Short Term Investments
206.12
-47.15%
390.02
-10.19%
434.28
-5.23%
458.25
Receivables
—
—
—
—
Prepaid Assets
—
—
—
—
Other Current Assets
9.16
+20.00%
7.63
-38.18%
12.35
-13.11%
14.21
Total Non Current Assets
4.23
+82.75%
2.31
-48.75%
4.51
-22.00%
5.79
Net PPE
1.09
-48.44%
2.12
-32.11%
3.12
-23.86%
4.09
Gross PPE
2.61
-18.91%
3.22
-15.37%
3.81
-12.85%
4.37
Accumulated Depreciation
-1.52
-37.65%
-1.10
-60.38%
-0.69
-152.38%
-0.27
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.50
+0.00%
0.50
+0.00%
0.50
+0.00%
0.50
Other Properties
0.64
-48.80%
1.25
-31.91%
1.83
-23.43%
2.39
Leases
1.48
+0.00%
1.48
+0.00%
1.48
+0.00%
1.48
Non Current Prepaid Assets
—
—
—
1.49
Other Non Current Assets
3.14
+1491.88%
0.20
-85.89%
1.40
-17.49%
1.69
Total Liabilities Net Minority Interest
39.78
+54.20%
25.80
-35.13%
39.78
+52.19%
26.14
Current Liabilities
39.78
+113.86%
18.60
-42.54%
32.38
+75.21%
18.48
Payables And Accrued Expenses
38.94
+118.73%
17.80
-43.69%
31.62
+78.05%
17.76
Payables
12.95
+190.38%
4.46
+4.84%
4.25
+60.45%
2.65
Accounts Payable
12.95
+190.38%
4.46
+4.84%
4.25
+66.68%
2.55
Current Accrued Expenses
26.00
+94.80%
13.35
-51.23%
27.36
+81.13%
15.11
Total Tax Payable
—
—
0.00
-100.00%
0.10
Income Tax Payable
—
—
0.00
-100.00%
0.10
Current Debt And Capital Lease Obligation
0.84
+5.38%
0.80
+5.26%
0.76
+5.41%
0.72
Current Capital Lease Obligation
0.84
+5.38%
0.80
+5.26%
0.76
+5.41%
0.72
Current Deferred Liabilities
—
—
—
—
Current Deferred Revenue
—
—
—
—
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
7.20
-2.73%
7.40
-3.37%
7.66
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.84
-48.72%
1.64
-31.67%
2.40
Long Term Capital Lease Obligation
0.00
-100.00%
0.84
-48.72%
1.64
-31.67%
2.40
Tradeand Other Payables Non Current
0.00
-100.00%
6.36
+10.39%
5.76
+9.57%
5.25
Other Non Current Liabilities
—
—
—
—
Stockholders Equity
275.43
-37.24%
438.87
-20.95%
555.19
-13.33%
640.57
Common Stock Equity
275.43
-37.24%
438.87
-20.95%
555.19
-13.33%
640.57
Capital Stock
0.08
-7.14%
0.08
+1.20%
0.08
+0.00%
0.08
Common Stock
0.08
-7.14%
0.08
+1.20%
0.08
+0.00%
0.08
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
78.13
-7.50%
84.46
+1.23%
83.44
+0.18%
83.29
Ordinary Shares Number
78.13
-7.50%
84.46
+1.23%
83.44
+0.18%
83.29
Additional Paid In Capital
797.75
-0.63%
802.77
+6.93%
750.74
+7.09%
701.05
Retained Earnings
-522.57
-43.48%
-364.22
-85.98%
-195.84
-227.05%
-59.88
Gains Losses Not Affecting Retained Earnings
0.17
-25.32%
0.23
+12.56%
0.21
+130.26%
-0.68
Other Equity Adjustments
0.17
-25.32%
0.23
+12.56%
0.21
+130.26%
-0.68
Total Equity Gross Minority Interest
275.43
-37.24%
438.87
-20.95%
555.19
-13.33%
640.57
Total Capitalization
275.43
-37.24%
438.87
-20.95%
555.19
-13.33%
640.57
Working Capital
271.21
-38.88%
443.75
-20.49%
558.08
-13.13%
642.44
Invested Capital
275.43
-37.24%
438.87
-20.95%
555.19
-13.33%
640.57
Total Debt
0.84
-48.66%
1.64
-31.64%
2.40
-23.11%
3.12
Capital Lease Obligations
0.84
-48.66%
1.64
-31.64%
2.40
-23.11%
3.12
Net Tangible Assets
275.43
-37.24%
438.87
-20.95%
555.19
-13.33%
640.57
Tangible Book Value
275.43
-37.24%
438.87
-20.95%
555.19
-13.33%
640.57
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-132.03
+2.56%
-135.50
-58.67%
-85.39
+29.42%
-120.98
Cash Flow From Continuing Operating Activities
-132.03
+2.56%
-135.50
-58.67%
-85.39
+29.42%
-120.98
Net Income From Continuing Operations
-158.35
+5.96%
-168.38
-23.85%
-135.96
-17.30%
-115.91
Depreciation Amortization Depletion
0.42
+0.00%
0.42
+0.00%
0.42
+60.00%
0.26
Depreciation And Amortization
0.42
+0.00%
0.42
+0.00%
0.42
+60.00%
0.26
Stock Based Compensation
20.72
-59.97%
51.77
+4.73%
49.43
+5.80%
46.72
Deferred Tax
-6.36
0.00
—
—
Deferred Income Tax
-6.36
0.00
—
—
Change In Working Capital
16.48
+320.47%
-7.48
-146.25%
16.16
+134.69%
-46.59
Change In Receivables
—
—
—
0.00
Change In Prepaid Assets
-1.53
-125.82%
5.91
+217.27%
1.86
+129.82%
-6.25
Change In Payables And Accrued Expense
21.14
+259.95%
-13.21
-192.01%
14.36
+136.26%
-39.61
Change In Accrued Expense
12.65
+194.26%
-13.42
-206.00%
12.66
+133.65%
-37.62
Change In Payable
8.49
+4019.90%
0.21
-87.89%
1.70
+185.78%
-1.98
Change In Account Payable
8.49
+4019.90%
0.21
-87.89%
1.70
+185.78%
-1.98
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
-2.94
0.00
-100.00%
0.10
+106.56%
-1.49
Change In Other Current Liabilities
-0.19
-8.57%
-0.17
-8.70%
-0.16
-121.05%
0.77
Investing Cash Flow
188.79
+236.50%
56.10
+39.21%
40.30
+108.85%
-455.41
Cash Flow From Continuing Investing Activities
188.79
+236.50%
56.10
+39.21%
40.30
+108.85%
-455.41
Net PPE Purchase And Sale
—
—
0.00
+100.00%
-1.94
Purchase Of PPE
—
—
0.00
+100.00%
-1.94
Capital Expenditure
—
—
—
-1.94
Net Investment Purchase And Sale
188.79
+236.50%
56.10
+39.21%
40.30
+108.89%
-453.47
Purchase Of Investment
-281.94
+38.87%
-461.18
+17.99%
-562.36
-3.12%
-545.35
Sale Of Investment
470.73
-9.00%
517.28
-14.17%
602.66
+555.89%
91.89
Financing Cash Flow
-25.75
-9742.32%
0.27
+3.89%
0.26
-30.54%
0.37
Cash Flow From Continuing Financing Activities
-25.75
-9742.32%
0.27
+3.89%
0.26
-30.54%
0.37
Net Common Stock Issuance
-25.46
0.00
—
0.23
Common Stock Payments
-25.52
0.00
—
—
Repurchase Of Capital Stock
-25.52
0.00
—
—
Proceeds From Stock Option Exercised
0.20
-24.72%
0.27
+3.89%
0.26
-30.54%
0.37
Net Other Financing Charges
-0.48
—
—
—
Changes In Cash
31.02
+139.20%
-79.13
-76.48%
-44.84
+92.22%
-576.02
Beginning Cash Position
64.70
-55.02%
143.82
-23.77%
188.66
-75.33%
764.68
End Cash Position
95.71
+47.94%
64.70
-55.02%
143.82
-23.77%
188.66
Free Cash Flow
-132.03
+2.56%
-135.50
-58.67%
-85.39
+30.53%
-122.92
Amortization Of Securities
-4.94
+58.18%
-11.82
+23.47%
-15.45
-182.63%
-5.46
Common Stock Issuance
0.06
0.00
—
0.23
Issuance Of Capital Stock
0.06
0.00
—
0.23
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category